This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Health Winners & Losers

Encysive Pharmaceuticals (ENCY) climbed 37 cents, or 21.8%, to $2.06, after announcing it retained Morgan Stanley to evaluate its strategic alternatives .

On the other end, Metabasis Therapeutics (MBRX) lost $3.91, or 56.7%, to $2.99 after disappointing phase II results from type 2 diabetes candidate and news that Schering-Plough (SGP) terminated its drug development agreement with the company on a hepatitis B treatment.

On the earnings front, Medtox Scientific (MTOX) lost $5.66, or 21.2%, to $21.02. The company reported net income for the quarter ended June 30 of $1.8 million, or 20 cents a share, compared to $1.3 million, or 15 cents a share, in the year-ago period. The Thomson Financial consensus target was 22 cents a share for the quarter.

Additionally in earnings, Johnson & Johnson (JNJ - Get Report) reported earnings of $3.1 billion, or $1.05 a share, for the quarter in comparison to $2.9 billion, or 98 cents a share, in 2006, and the Thomson Financial consensus target of $1 a share. Shares of the company, however, were down $1.17, or 1.8%, to $62.64.

Forest Labs (FRX) earned $268 million, or 83 cents a share, in the quarter ended June 30, compared to $200 million, or 62 cents a share, in the year-ago quarter. The company beat the consensus target of 77 cents a share, but was down 88 cents, or 1.9%, to $45.79.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
COR $60.80 5.57%
DRRX $1.01 -0.98%
FRX $99.00 -0.77%
JNJ $101.70 -0.03%
AAPL $93.70 -0.60%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs